PRECISION 1: A phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2.

Authors

null

Gopa Iyer

Memorial Sloan Kettering Cancer Center, New York, NY

Gopa Iyer , David J. Kwiatkowski , Li Ding , Anita N. Schmid , Willis H. Navarro , Jordi Rodon Ahnert

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05103358

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS526)

DOI

10.1200/JCO.2024.42.4_suppl.TPS526

Abstract #

TPS526

Poster Bd #

M22

Abstract Disclosures